Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OMER
HoldHot AirOmeros Corporation · Healthcare · United States · $1.3B · Avg Vol: $38M/d
COMPANY DESCRIPTION
Omeros Corporation is a biopharmaceutical company developing and commercializing small-molecule and protein therapeutics for inflammation, complement-mediated diseases, and central nervous system disorders, with OMIDRIA as its primary commercial product. It relies on its proprietary G protein-coupled receptor platform and complement inhibitor programs for drug discovery and development. Omeros is a biotechnology company with an emphasis on novel therapeutic targets, aiming to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 125.6M | 197.8M | — |
| EPS | 0.76 | -1.88 | -2.70 | -0.05 | — | 1.65 | — | — | — |
| Shares | 62.8M | 61.1M | 58.0M | 71.7M | +14.1% | 72.4M | — | — | — |
| Debt | 342.0M | 236.5M | 207.0M | 239.1M | -11.2% | 296.9M | — | — | — |
| Equity | 85.7M | -25.0M | -182.6M | -121.2M | — | — | — | — | — |
| Op CF | -86.5M | 74.7M | -148.8M | -116.1M | — | -68.7M | — | — | — |
| Inv CF | -127.6M | 27.5M | 82.2M | 164.5M | — | — | — | — | — |
| Fin CF | 124.2M | -106.1M | 62.9M | -42.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OMER are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OMER | Omeros Corporation(you) | $1.3B | 48 | Hold |
| ANL | Adlai Nortye Group Ltd. | $890M | 49 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| MNPR | Monopar Therapeutics Inc. | $751M | 47 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| FTRE | Fortrea Holdings Inc. | $1.8B | 60 | Hold |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%